Flow cytometry (transfected cell) analysis of 293T-SARS-CoV-2 spike cells were treated with SARS-CoV-2 S recombinant human monoclonal antibody, clone 7F7 (Cat # RAB01068-M01J). This antibody efficiently bound to 293T- SARS-CoV-2 spike cells.
Inhibition Assay
Protein receptor-binding inhibition assay of spike-His protein was treated with SARS-CoV-2 S recombinant human monoclonal antibody, clone 7F7 (Cat # RAB01068-M01J), and then added into 293T-ACE2 cells. Data were analyzed by flow cytometer. Binding affinity of spike-His protein to ACE2 is totally blocked by this antibody.
Neutralization
Neutralization analysis of pseudovirus was treated with SARS-CoV-2 S recombinant human monoclonal antibody, clone 7F7 (Cat # RAB01068-M01J), and then added into 293T-ACE2 cells. Luciferase activity was measured 48 hours post infection.
Neutralization
Neutralization analysis of variant pseudovirus was treated with SARS-CoV-2 S recombinant human monoclonal antibody, clone 7F7 (Cat # RAB01068-M01J), and then added into 293T-ACE2 cells. Luciferase activity was measured 48 hour post infection.
Neutralization
Cytopathic effect (CPE) based live virus neutralization analysis with human IgG1 isotype control and SARS-CoV-2 S recombinant human monoclonal antibody, clone 7F7 (Cat # RAB01068-M01J). The antibody solutions (100 uL) were mixed in 1:1 (v/v) with suspension containing 200 TCID50 of SARS-CoV-2 virus.
Antibody Kinetics
Antibody kinetics with SARS-CoV-2 S recombinant human monoclonal antibody, clone 7F7 (Cat # RAB01068-M01J) and data were analyzed by biacore surface plasmon resonance.
ELISA analysis coated mucin (100 ug/mL) with SARS-CoV-2 S recombinant human monoclonal antibody, clone 7F7 (Cat # RAB01068-M01J).
Neutralization
In in vivo neutralization analysis, hamsters received 2 doses of SARS-CoV-2 S recombinant human monoclonal antibody, clone 7F7 (Cat # RAB01068-M01J) by intraperitoneal injection and then were infected with 3 doses pseudovirus through intanasal injection. Lung tissues were collected one day post last dose pseudovirus treatment. Luciferase gene expression level was detected by QPCR.
Neutralization
In in vivo nasal prophylaxis neutralization analysis. Hamsters were infected with either B.1.1.28.1 (upper panel) or B.1.617.2 (lower panel) variant spike pseudovirus 2 hours after receiving SARS-CoV-2 S recombinant human monoclonal antibody, clone 7F7 (Cat # RAB01068-M01J). Lung tissues were collected one day after the last dose of pseudovirus treatment. Luciferase gene expression level was detected by qPCR.